Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.

摘要: There is an increasing range of therapeutic options for primary antibody-deficient patients who require replacement immunoglobulin. These include intravenous immunoglobulin (IVIg), subcutaneous (SCIg), rapid push SCIg and most recently recombinant human hyaluronidase-facilitated (fSCIg). Advantages fSCIg fewer needle punctures, longer infusion intervals improved adverse effect profile relative to IVIg. Limited real-life experience exists concerning the practical aspects switching or starting on fSCIg. We describe first 14 have been treated with at Immunodeficiency Centre Wales (ICW), representing more than 6 patient-years experience. The regimen was well tolerated, high levels satisfaction no increase in training requirement, including a treatment-naive patient. Two discontinued due pain swelling site, one paused therapy following post-infusion migraines. Ultrasound imaging paired conventional facilitated demonstrated clear differences space distribution associated 10-fold rate volume delivery Patient profiles those choosing fell into two main categories: experiencing clinical problems their current treatment seeking greater convenience flexibility. When introducing fSCIg, consideration type programming pump, gauge length, up-dosing schedule, home patient information are important, as these may differ from SCIg. This paper provides guidance administration, outcomes help inform decision-making this new modality.